Cardiol Therapeutics Inc
TSX:CRDL

Watchlist Manager
Cardiol Therapeutics Inc Logo
Cardiol Therapeutics Inc
TSX:CRDL
Watchlist
Price: 1.81 CAD -3.21%
Market Cap: 147.7m CAD
Have any thoughts about
Cardiol Therapeutics Inc?
Write Note

Cardiol Therapeutics Inc
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cardiol Therapeutics Inc
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
Cardiol Therapeutics Inc
TSX:CRDL
Depreciation & Amortization
-CA$391.4k
CAGR 3-Years
-21%
CAGR 5-Years
-27%
CAGR 10-Years
N/A
Canopy Growth Corp
TSX:WEED
Depreciation & Amortization
-CA$25.4m
CAGR 3-Years
28%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Sundial Growers Inc
NASDAQ:SNDL
Depreciation & Amortization
-CA$60.2m
CAGR 3-Years
-134%
CAGR 5-Years
-132%
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Depreciation & Amortization
-$3.8m
CAGR 3-Years
-1%
CAGR 5-Years
-17%
CAGR 10-Years
N/A
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Depreciation & Amortization
-$1.3m
CAGR 3-Years
12%
CAGR 5-Years
-165%
CAGR 10-Years
N/A
C
Curaleaf Holdings Inc
CNSX:CURA
Depreciation & Amortization
-$215m
CAGR 3-Years
-54%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Cardiol Therapeutics Inc
Glance View

Market Cap
147.7m CAD
Industry
Pharmaceuticals

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on developing anti-inflammatory therapies for cardiovascular disease (CVD). The company is headquartered in Oakville, Ontario and currently employs 11 full-time employees. The company went IPO on 2018-12-20. The firm's lead product, CardiolRx, is a pharmaceutically produced oral cannabidiol formulation that is in a Phase II/III study in hospitalized patients testing positive for COVID-19 with a prior history of, or risk factors for, cardiovascular disease. Cardiol has also received clearance from the Food and Drug Administration (FDA) for its investigational new drug (IND) application for a Phase II international trial that investigates the anti-inflammatory and anti- fibrotic properties of CardiolRx in patients with acute myocarditis, which is a common cause of sudden cardiac death in people under 35 years of age. In addition, Cardiol is developing a subcutaneous formulation of CardiolRx and other anti-inflammatory therapies for the treatment of chronic heart failure.

CRDL Intrinsic Value
0.73 CAD
Overvaluation 60%
Intrinsic Value
Price

See Also

What is Cardiol Therapeutics Inc's Depreciation & Amortization?
Depreciation & Amortization
-391.4k CAD

Based on the financial report for Sep 30, 2024, Cardiol Therapeutics Inc's Depreciation & Amortization amounts to -391.4k CAD.

What is Cardiol Therapeutics Inc's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
-27%

Over the last year, the Depreciation & Amortization growth was -63%. The average annual Depreciation & Amortization growth rates for Cardiol Therapeutics Inc have been -21% over the past three years , -27% over the past five years .

Back to Top